Sars-cov-2 neutralizing antibody or fragment thereof

Patent metadata

Field	Value
Publication number	US-2023348573-A1
Application number	US-202118027999-A
Country	US
Kind code	A1
Filing date	Sep 24, 2021
Priority date	Sep 25, 2020
Publication date	Nov 2, 2023
Grant date	—

Abstract

An antibody against spike protein of SARS-CoV-2 is provided, the antibody having a specific heavy chain variable region and a specific light chain variable region, or a fragment of the antibody, the antibody or fragment thereof inhibiting the binding between the spike protein of SARS-CoV-2 and ACE2, the antibody or fragment thereof inhibiting SARS-CoV-2 infection; and a pharmaceutical composition including the antibody or fragment thereof and a pharmaceutically acceptable carrier, the pharmaceutical composition including two or more kinds of the antibody or fragment thereof.

First claim

1 . An antibody against spike protein of SARS-CoV-2, or a fragment of the antibody, the antibody or fragment thereof comprising a heavy chain variable region and a light chain variable region described in any one of the following items (1) to (26):
(1) a heavy chain variable region in which complementarity-determining regions (CDR) 1, CDR2, and CDR3 determined according to a Kabat numbering system include amino acid sequences set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively; (2) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, respectively; (3) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18, respectively; (4) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24, respectively; (5) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30, respectively; (6) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:34, SEQ ID NO:35, and SEQ ID NO:36, respectively; (7) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:37, SEQ ID NO:38, and SEQ ID NO:39, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:40, SEQ ID NO:41, and SEQ ID NO:42, respectively; (8) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:46, SEQ ID NO:47, and SEQ ID NO:48, respectively; (9) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:52, SEQ ID NO:53, and SEQ ID NO:54, respectively; (10) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:55, SEQ ID NO:56, and SEQ ID NO:57, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:58, SEQ ID NO:59, and SEQ ID NO:60, respectively; (11) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:63, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66, respectively; (12) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:67, SEQ ID NO:68, and SEQ ID NO:69, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:70, SEQ ID NO:71, and SEQ ID NO:72, respectively; (13) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:73, SEQ ID NO:74, and SEQ ID NO:75, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:76, SEQ ID NO:77, and SEQ ID NO:78, respectively; (14) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:79, SEQ ID NO:80, and SEQ ID NO:81, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:84, respectively; (15) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:87, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:88, SEQ ID NO:89, and SEQ ID NO:90, respectively; (16) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:91, SEQ ID NO:92, and SEQ ID NO:93, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:94, SEQ ID NO:95, and SEQ ID NO:96, respectively; (17) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:97, SEQ ID NO:98, and SEQ ID NO:99, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:100, SEQ ID NO:101, and SEQ ID NO:102, respectively; (18) a heavy chain variable region in which CDR1, CDR2, and CDR3 determined according to the Kabat numbering system include amino acid sequences set forth in SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:105, respectively, and a light chain variable region in which CDR1, CDR2, and CDR3 determined acc

Assignees

• Univ Keio
• Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
• Riken
• Univ Shiga Medical Science
• Univ Tokyo

Inventors

• Takeshita Masaru
• Takeuchi Tsutomu
• Suzuki Katsuya
• Saya Hideyuki
• Takahashi Yoshimasa
• MORIYAMA Saya
• Fukuyama Hidehiro
• Okamura Chieko
• Shirouzu Mikako
• Matsumoto Takehisa
• KAMADA Katsuhiko
• Itoh Yasushi
• Ishigaki Hirohito
• Nakayama Misako
• Kitagawa Yoshinori
• Kawaoka Yoshihiro

Classifications

• C07K16/104 Primary

  Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2] · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title